Michael Barbella

1 week ago | mpo-mag.com | Michael Barbella |Sam Brusco

Diality Inc. has welcomed Dr. Chris Springer to its Board of Directors. He brings 30 years of commercial and strategic experience in the pharmaceutical and biotech industries to the board. As Chief Strategy Officer for Vifor Pharma, Dr. Springer created a joint renal-drug company between Vifor Pharmaceuticals and Fresenius Medical Care as well as orchestrated a series of licensing deals and acquisitions, culminating in the acquisition of Vifor Pharma by CSL for $11.7 billion.

1 week ago | mpo-mag.com | Michael Barbella |Sam Brusco

The Cystic Fibrosis Foundation has made an equity investment of up to $2.3 million (circa £1.7 million) in Owlstone Medical for the development of a breath test for Pseudomonas aeruginosa (PA) detection in cystic fibrosis (CF) patients. The breath-based test would be suitable for both early detection of new PA infection and monitoring the chronic infection in CF patients, with diagnostic accuracy at least comparable to sputum culture tests.

1 week ago | mpo-mag.com | Michael Barbella |Sam Brusco

Panther Life Sciences has appointed Dr. Matthew Hepburn as executive vice president of Research and Development. In this role, Dr. Hepburn will drive Panther’s strategic commitment to commercialize its patented MAP technology, with a primary focus on reducing time-to-market and delivering the first commercial product to customers within the next two years.

1 week ago | odtmag.com | Michael Barbella

As an advocate for expanded patient access to high-quality care, the American Association of Orthopaedic Surgeons (AAOS) is voicing its support for proposed federal legislation that would improve healthcare access in rural areas through expanded physician-led hospitals. First submitted in the 118th Congress, the Physician Led and Rural Access to Quality Care Act (H.R. 2191)—introduced by U.S. Reps.

1 week ago | mpo-mag.com | Sam Brusco |Michael Barbella

LUMA Vision, a company focused on advanced cardiac imaging and navigation, has earned U.S. Food and Drug Administration (FDA) clearance of its Verafeye visualization platform. The catheter-based imaging system offers real-time, two and four-dimensional, 360-degree visualization—especially helpful for complex electrophysiology and structural heart procedures. The system is prepared for magnetic tracking and navigation of third-party catheters.